Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

  title={Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.},
  author={Kris V. Kowdley and Eric J. Lawitz and Fred P Poordad and Daniel E. Cohen and David R Nelson and Stefan Zeuzem and Gregory T. Everson and Paul Y. Kwo and Graham R. Foster and Mark S Sulkowski and Wangang Xie and Tami J. Pilot-Matias and George Liossis and Lois Larsen and Amit Khatri and Thomas J. Podsadecki and Barry Bernstein},
  journal={The New England journal of medicine},
  volume={370 3},
BACKGROUND An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. The addition of another potent agent, the NS5A inhibitor ABT-267, may improve efficacy, especially in difficult-to-treat patients. This study was designed to evaluate multiple regimens of direct-acting antiviral… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 117 extracted citations


Publications referenced by this paper.
Showing 1-10 of 18 references

High sustained virologic response rate in treatment-naive HCV genotype 1A and 1B patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results

  • M Sulkowski, M Rodriguez-Torres, E Lawitz
  • J Hepatol 2012;56:Suppl:S560. abstract
  • 2012

Pharmacokinetics and tolerability of the HCV protease inhibitor ABT - 450 following single ascending doses in healthy adult volunteers with and without ritona

  • R Menon, C Klein, A Lawal
  • Gastroenterology
  • 2012

Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects

  • E Lawitz, T Marbury, A Campbell
  • J Hepatol 2012;56:Suppl 2:S469-S470. abstract
  • 2012

Similar Papers

Loading similar papers…